Nilapani is an oral inhibitor of poly ADP ribose polymerase (PARP), which can inhibit the repair of DNA damage by cells. For cancer cells with BRCA gene mutation, if PARP activity is further inhibited, these cells will produce a lot of DNA damage during division, leading to cancer cell death.

In terms of safety, Nilapani mainly showed thrombocytopenia (33.8%), anemia (25.3%) and neutropenia (19.6%). Because it will lead to thrombocytopenia, poverty and other problems, your aunt's body immunity will be much worse In this case, two suggestions are put forward. One thing is that patients should choose some supplements and foods that can replenish blood for patients in their daily diet. In addition, in order to reduce the drug resistance of nilapani in the treatment of breast cancer, I suggest that patients can be combined with anti-vascular therapy, and Rg3 in ginseng can be used as an adjuvant therapy to improve patients' immunity, reduce adverse drug reactions and enhance chemotherapy sensitivity. In addition to improving patients' immunity, enhancing efficiency and reducing toxicity, it can also inhibit the growth of tumor cells and induce tumor cell apoptosis, which is achieved by blocking the nutrient sources needed by tumor blood vessels.